title: [Technological evolutions in blood donation screening and their impact on the residual risk].
abstract: During the two last decades, the risk of viral transfusion transmission for some infectious agents (HIV, HCV, HBV and HTLV) has been markedly reduced by improved donor screening, improvements of serological assays and the implementation of minipool nucleic acid testing for HIV-1 and HCV viruses. However, implementation during the year 2010 of nucleic acid testing for the detection of HIV RNA, HCV RNA and HBV DNA in a single triplex assay may provide additional safety, especially after acute infection during the window period. New Procleix(®) Tigris(®) technology (Novartis) allow the French blood screening laboratories to answer their actual requirements in terms of security and throughput and to implement nucleic acid testing in case of emergent risks requiring a direct detection of viruses. Furthermore, Tigris(®) is a fully automated system with high level of security during the analytical process, reducing the number of invalid or non-available results observed with the previous semi-automated technologies. Moreover, renewal of material by fully automated and secure systems, especially for the critical step of sample pipeting, may provide additional safety in blood screening laboratories.
authors.affiliation: Laboratoires QBD, site de Metz-Tessy, Établissement français du sang Rhône-Alpes, route de Pringy, 74370 Metz-Tessy, France. valerie.barlet@efs.sante.fr
authors.forename: V
authors.initials: V
authors.lastname: Barlet
mesh_terms: D001331:Automation; D001782:Blood Donors; D058731:Blood Safety / Q000295:instrumentation / Q000379:methods / Q000592:standards*; D017848:Blood-Borne Pathogens; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D021821:Communicable Diseases, Emerging / Q000517:prevention & control / Q000635:transmission; D004279:DNA, Viral / Q000097:blood; D046148:Donor Selection / Q000379:methods* / Q000592:standards / Q000639:trends; D005602:France / Q000453:epidemiology; D016679:Genome, Viral; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D007753:Laboratories / Q000592:standards; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D021141:Nucleic Acid Amplification Techniques / Q000295:instrumentation / Q000379:methods*; D011786:Quality Control; D012367:RNA, Viral / Q000097:blood; D015203:Reproducibility of Results; D012306:Risk; D012680:Sensitivity and Specificity; D065227:Transfusion Reaction; D014766:Viremia / Q000175:diagnosis* / Q000821:virology; D014777:Virus Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission
chemical_list: D004279:DNA, Viral; D012367:RNA, Viral